QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies

Pant, Anjali; Sharma, Gajanand; Saini, Sumant; Kaur, Gurjeet; Jain, Atul; Thakur, Anil; Singh, Bhupinder

doi:10.1007/s13346-023-01427-3

Drug Deliv. and Transl. Res.

2023

DOI: 10.1007/s13346-023-01427-3

|View full text |Cite

QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies

Anjali Pant,

Gajanand Sharma,

Sumant Saini

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Membrane Permeability and Drug Targeting Potential of Phospholipid‐Based Nanocarriers in Lung Cancer Therapy

Sen,

Sarkar,

Das

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Lung cancer has become the leading cause of cancer‐related deaths, surpassing all other forms of cancer. Among lung cancers, non‐small cell lung cancer (NSCLC) accounts for approximately 85% of cases. The use of tobacco, genetic traits, and radiation exposure are amongst the major reasons of lung cancer. The ongoing research in the medical field has considered the efficacy of nanocarriers in targeting various cancer cells. Among several biomaterials, lipid‐based nanocarriers have gained special attention due to their excellent compatibility, improved targeting efficacy, and encapsulation ability of diverse therapeutic agents. Phospholipids are naturally occurring amphiphilic moieties found in all living creatures. The presence of phospholipids in biomembrane aids the permeability of phospholipid‐based drug carrier. It can also facilitate targeting of therapeutic agents to cancer microenvironment without degrading the encapsulated drug. Phospholipids can be employed to develop conjugated nanocarriers and vesicular nanoformulation that can result in prolonged circulatory half‐life and controlled release of drugs. Phospholipids are also suitable biomaterials to attach a ligand for tissue‐specific targeting. Recent researches have reported effective targeting of chemotherapeutic agents, genes, and vaccines through phospholipid‐based nanocarriers to lung cancer cells. This review focuses on the rationality and applications of phospholipid‐based nanocarriers in lung cancer therapy.

show abstract

Membrane Permeability and Drug Targeting Potential of Phospholipid‐Based Nanocarriers in Lung Cancer Therapy

Sen,

Sarkar,

Das

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies

Cited by 1 publication

References 81 publications

Membrane Permeability and Drug Targeting Potential of Phospholipid‐Based Nanocarriers in Lung Cancer Therapy

Membrane Permeability and Drug Targeting Potential of Phospholipid‐Based Nanocarriers in Lung Cancer Therapy

Contact Info

Product

Resources

About